Tapering Lorazepam and Managing Insomnia and Panic Attacks

Introduction to Tapering

The American Academy of Sleep Medicine recommends tapering lorazepam gradually over several weeks to months, with a reduction of 0.25 mg every 1-2 weeks, while introducing non-benzodiazepine alternatives such as trazodone 25-100 mg for sleep and an SSRI like sertraline for panic attacks 1

Trazodone, 25-100 mg at bedtime, is a non-habit forming alternative that addresses both sleep initiation and maintenance, particularly effective for patients with comorbid depression/anxiety, and should be started at 25 mg and titrated up as needed 1
Mirtazapine, 7.5-15 mg at bedtime, is effective for sleep with additional antidepressant benefits, particularly useful for patients with comorbid depression, anxiety, or appetite issues 1
Non-benzodiazepine hypnotics, such as eszopiclone 1-3 mg, zolpidem 5-10 mg, and zaleplon 5-10 mg, can be used as alternatives for sleep maintenance and onset 1
Ramelteon, 8 mg at bedtime, is a melatonin receptor agonist that is non-scheduled and primarily used for sleep onset difficulties, and is safe for patients with a history of substance use disorders 1

A structured tapering approach is essential, with an initial phase of 2-4 weeks, reducing the dose by 0.25 mg every 1-2 weeks, and monitoring for withdrawal symptoms using a standardized assessment 1
Cognitive behavioral therapy for insomnia (CBT-I) should be implemented during the tapering process to improve outcomes for both insomnia and panic 1

Elderly patients require lower starting doses and slower tapering 2
It is crucial to monitor for serotonin syndrome if combining multiple serotonergic agents, and to avoid combining benzodiazepines with opioids due to the risk of respiratory depression 2
Implementing sleep hygiene measures concurrently with medication changes is recommended 2

Tapering too quickly increases the risk of withdrawal and relapse 2
Ignoring breakthrough symptoms can lead to severe consequences, and it is essential to temporarily pause the taper if severe symptoms emerge 2
Overlooking comorbidities, such as untreated depression or anxiety, can worsen insomnia 2
Polypharmacy, or adding multiple sedating agents, increases the fall risk, especially in elderly patients 2
Neglecting non-pharmacological approaches, such as CBT-I, can lead to poorer long-term outcomes compared to medications alone 2